Hepatitis B virus (<scp>HBV</scp>) reverse seroconversion (<scp>RS</scp>) can be prevented even in non‐responders to hepatitis B vaccine after allogeneic stem cell transplantation: long‐term analysis of intervention in <scp>RS</scp> with vaccine for patients with previous <scp>HBV</scp> infection

Abstract

These results demonstrated the long-term effects of HBV vaccine for preventing HBV-RS after alloHSCT. Of note, no HBV-RS occurred, even in patients who did not achieve conversion into HBsAb positivity after vaccination.